OBJECTIVE: The objective of this study was to assess the role of stereotactic radiosurgery in the management of newly diagnosed multiple intracranial @entity3 from known primary @entity5 locations. METHODS: Fifty (29 @entity1 and 21 @entity1 ) @entity1 received radiosurgery for newly diagnosed 3 or more metastatic @entity1313 . Their mean age was 53 years. @entity2 was the most common primary @entity5 (66%). RESULTS: Arrest in the growth of @entity5 was achieved in 41 (82%) @entity1 . Eight @entity1 (16%) required further intervention for @entity5 in other brain locations. Mean survival after diagnosis of @entity75 was 12 months and the @entity75 -controlled period was 19 months. The period of @entity75 control prolonged (P=.03) with decreasing @entity5 volumes (<10 mL). Control of treated @entity5 positively affected survival after diagnosis of @entity75 (P=.0001). CONCLUSION: Radiosurgery as an adjuvant improves survival in @entity1 with @entity5 who have newly diagnosed multiple intracranial @entity3 by arresting the growth of @entity5 .

Role of stereotactic radiosurgery as a primary treatment option in the management of newly diagnosed multiple (3-6) intracranial XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men'] @entity1313 :: ('MESH:D001932', 'Disease') :: ['brain tumors'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'irradiated tumors', 'cancer', 'tumors'] @entity75 :: ('MESH:D001927', 'Disease') :: ['brain disease'] @entity2 :: ('MESH:D008175', 'Disease') :: ['Lung cancer'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']
@entity3 :: (MESH:D009362,Disease) :: ['metastases']
